CJC-1295/Ipamorelin Dosing Information
There are no FDA-approved dosing guidelines, clinical practice guidelines, or high-quality evidence supporting the use of CJC-1295 or Ipamorelin in clinical practice. These peptides remain investigational compounds without established safety or efficacy data for routine therapeutic use.
Research-Based Dosing from Clinical Trials
CJC-1295 Dosing from Human Studies
Single-dose administration:
- Research trials used subcutaneous doses ranging from 30 to 60 mcg/kg as single injections in healthy adults 1
- These doses produced sustained GH elevation for 6+ days and IGF-I elevation for 9-11 days 1
- The estimated half-life was 5.8-8.1 days 1
Multiple-dose administration:
- Weekly or biweekly dosing schedules were studied, with doses of 30-60 mcg/kg administered subcutaneously 1
- IGF-I levels remained elevated for up to 28 days after multiple doses 1
- For a 70 kg adult, this translates to approximately 2.1-4.2 mg per injection (30-60 mcg/kg × 70 kg)
Normalization of growth in animal models:
- Daily administration of 2 mcg per dose was required to normalize growth in GHRH-deficient mice 2
- Dosing every 48-72 hours was less effective than daily administration 2
Ipamorelin Dosing from Research Studies
Animal studies only:
- In conscious swine, the effective dose (ED50) was 2.3 nmol/kg subcutaneously 3
- Maximum efficacy (Emax) occurred at doses producing 65 ng GH/ml plasma 3
- Ipamorelin demonstrated selectivity for GH release without affecting ACTH or cortisol, even at doses 200-fold higher than the ED50 3
Critical Safety and Regulatory Warnings
Regulatory status:
- CJC-1295 is classified as a Prohibited Substance under Section S2 of the WADA Prohibited List as a growth hormone-releasing factor 4
- These compounds are being manufactured and distributed illicitly, often before completing clinical trials 4
- CJC-1295 has been identified in unknown pharmaceutical preparations submitted to law enforcement 4
Clinical trial limitations:
- The longest human trial duration was only 49 days 1
- No serious adverse reactions were reported in short-term studies, but long-term safety is completely unknown 1
- There are no data on morbidity, mortality, or quality-of-life outcomes in any patient population
Detection and abuse potential:
- CJC-1295 covalently binds to plasma proteins (particularly albumin), making detection difficult 5
- The compound is being used within bodybuilding communities despite lack of approval 4
- Specialized LC-MS/MS methods are required for detection in biological samples 5
Why These Compounds Should Not Be Used Clinically
No established therapeutic indication:
- Neither compound has completed Phase III clinical trials or received FDA approval
- No comparative effectiveness data exist versus approved GH therapies
- No data on patient-centered outcomes (morbidity, mortality, quality of life)
Unknown long-term risks:
- Chronic GH/IGF-I elevation carries theoretical risks of malignancy, metabolic dysfunction, and cardiovascular disease
- The 28-day sustained IGF-I elevation seen with CJC-1295 has unknown clinical consequences 1
- No post-marketing surveillance data exist
Legal and ethical concerns:
- Use outside of approved clinical trials may violate federal regulations
- Patients obtaining these compounds are likely receiving products of unknown purity and potency
- No quality control or pharmaceutical-grade manufacturing standards apply to illicit preparations
If a patient presents having used these compounds, document the exposure, monitor for adverse effects (particularly cardiovascular and metabolic), and strongly advise discontinuation pending completion of legitimate clinical trials.